Rare Disease Advisor
While GHK-Cu is generally well-tolerated in topical research, certain contraindications or precautions should be considered, especially for systemic research or in specific populations: Systemic Research: For systemic applications, GHK-Cu is generally not recommended for subjects who are pregnant, breastfeeding, have active cancer, or suffer from Wilsons disease (a condition involving copper accumulation)
The administered therapy was a one-time intraperitoneal application of the stable gastric pentadecapeptide BPC 157, much like the one-time engraftment of neural stem cells [16] or bone marrow stromal cells [17] into the lesion site
The research is preclinical and ongoing, which is why BPC-157 is prescribed off-label
At six months post-op, the patient was back to full duty, loading and unloading heavy cargo and getting into and out of an 18-wheeler truck
Prescribers should document their clinical rationale, including the absence of contraindications, in the patient's medical record